lun wen：治疗癌症药物的研究
二甲双胍是一种治疗2型糖尿病的药物。该药物通过靶向AMP活化蛋白激酶(AMPK)起作用。这使得肌肉利用体内的葡萄糖。最近的研究表明，AMPK酶被用来调控蛋白激酶LKB1。这是一种肿瘤抑制剂。因此，本研究的目的是展示二甲双胍在降低糖尿病患者患癌症风险中的应用。以这一因素为背景，进行了研究，了解二甲双胍除了用于控制2型糖尿病的影响。
参与者:
使用Tayside数据库对一项试点病例对照研究进行了测试。该数据库名为糖尿病临床信息系统。对数据库中的糖尿病患者进行随机研究。所有的参与者都患有糖尿病，研究中的一些人患上了癌症，而其他人没有任何癌症的迹象。
lun wen：治疗癌症药物的研究
方法:
为此测试进行了队列研究。队列研究是一组具有相似特征的人。在这种情况下，是患者发展成糖尿病。本研究使用了测试用例和控制项。本研究采用条件logistic回归分析。病例对照研究采用条件logistic回归。有一种情况的参与者与没有这种情况的研究参与者进行配对。在这种情况下，参与者都是糖尿病患者，其中一组患有癌症，另一组没有癌症。然而，有第三个对照组来验证药物的影响。由于这是一项队列研究，从1993年开始考虑对患者使用二甲双胍。
结果:
结果表明，没有真正确凿的证据表明，给药已经导致预防或减少了癌症进展的影响。需要更多的参与者来了解这种药物的影响。
结论:
由于已经证明蛋白激酶LKB1可以由二甲双胍药物控制，该药物治疗癌症的潜力已经确定。然而，本研究的结论是，在确定该药物的疗效时，应进行更多的分析和病理生理周期分析。未来的研究将致力于开发这种治疗癌症的药物。
lun wen：治疗癌症药物的研究
Metformin is a drug that is given to the Diabetes type 2 condition. This drug works by targeting the AMP activated protein kinase (AMPK). This makes the muscles use the glucose in the body. Recent research has indicated that AMPK enzyme is used to regulate the protein kinase LKB1. This is a tumor suppressor. Hence, the purpose of this research was to show the use of Metformin for the Diabetes patients in reducing the risk of developing cancer. Using this factor as the background, there was research undertaken to understand the impact of Metformin apart from its use in controlling of the type 2 Diabetes condition.
Participants:
A pilot case controlled study was tested with the database Tayside. The database was titled diabetes clinical information system. A random study was tested on the diabetic patients in the database. All the participants had diabetes 2 condition, some of the people in the study had developed cancer while the others did not have any evidence of cancer.
lun wen：治疗癌症药物的研究
Method:
A cohort study was undertaken for this testing. A cohort study is a group of people with similar characteristics. In this case, it was the patients who had developed Diabetes. There were the test cases and the controls used for this research. Conditional logistic regression was done for this research. Condition logistic regression is used in the case-control study. The participant with one condition is matched with a study participant without the condition. In this case, the participants were all diabetes patients of which one group had cancer and the other group did not have cancer. However, there was the third controlled group to verify the impact of the drug. Since this was a cohort study, the metformin administration of the patients from 1993 was considered.
Result:
The results indicated that there was no real conclusive evidence that the administration of the drug had caused the prevention or reduced the impact of cancer progression. More participants were needed to understand the impact of the drug.
Conclusion:
Since it has been proven that protein kinase LKB1 can be controlled by Metformin drug, the potential of the drug to handle the condition of cancer is established. However, it was concluded in this research that there should be more analysis and pathophysiological cycles analyzed in determining the efficacy of the drug. Future research will be directed towards developing this drug for the treatment of cancer.
